FierceBiotech Mar 24, 2026 Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
FierceBiotech Mar 23, 2026 Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
FierceBiotech Mar 23, 2026 Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
FierceBiotech Mar 23, 2026 FDA solicits feedback on controversial national priority voucher review pathway
FierceBiotech Mar 23, 2026 Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
FierceBiotech Mar 23, 2026 Stryker continues to bring hacked systems back online after patients delay surgeries
FierceBiotech Mar 23, 2026 Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
FierceBiotech Mar 20, 2026 Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
FierceBiotech Mar 20, 2026 Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral
FierceBiotech Mar 20, 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
FierceBiotech Mar 20, 2026 Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin